Pfizer Highlights Next I&I Star As Xeljanz Sales Fall

 
• By Jessica Merrill

The company is looking to refuel its immunology & inflammation portfolio as Xeljanz safety takes a toll and the franchise approaches loss of exclusivity.

stars
Pfizer highlighted etrasimod as a next portfolio star • Source: Shutterstock

More from Immunological

More from Therapy Areas